Modelling of Tirapazamine Effects on Solid Tumour Morphology

  • N. Kazmi
  • M. A. Hossain
  • R. M. Phillips
Part of the Advances in Intelligent and Soft Computing book series (AINSC, volume 93)


Bioreductive drugs are in clinical practice to exploit the resistance from tumour microenvironments especially in the hypoxic region of tumour. We presented a tumour treatment model to capture the pharmacology of one of the most prominent bioreductive drugs, Tirapazamine (TPZ) which is in clinical trials I and II. We calculated solid tumour mass in our previous work and then integrated that model with TPZ infusion. We calculated TPZ cytotoxicity, concentration, penetration with increasing distance from blood vessel and offered resistance from microenvironments for drug penetration inside the tumour while considering each cell as an individual entity. The impact of these factors on tumour morphology is also showed to see the drug behaviour inside animals/humans tumours. We maintained the heterogeneity factors in presented model as observed in real tumour mass especially in terms of cells proliferation, cell movement, extracellular matrix (ECM) interaction, and the gradients of partial oxygen pressure (pO2) inside tumour cells during the whole growth and treatment activity. The results suggest that TPZ high concentration in combination with chemotherapy should be given to get maximum abnormal cell killing. This model can be a good choice for oncologists and researchers to explore more about TPZ action inside solid tumour.


AQ4N Extra Cellular Matrix Hypoxia and Tirapazamine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Perumpanani, A.J., Byrne, H.M.: Extracellular matrix concentration exerts selection pressure on invasive cells. Journal of Cancer 35, 1274–1280 (1999)CrossRefGoogle Scholar
  2. Minchinton, A.I., Tannock, I.F.: Drug penetration in solid tumours. Nature Reviews Cancer 6, 583–592 (2006)CrossRefGoogle Scholar
  3. Anderson, A.R.A., Weaver, A.M., Cummings, P.T., Quaranta, V.: Tumor morphology and phenotypic evolution by selective pressure from the microenvironment. Cell 127 (2006)Google Scholar
  4. Anderson, A.R.A., Chaplain, M.A.J., Newman, E.L., Steele, R.J.C.: Mathematical modelling of tumour invasion and metastasis. Journal of Theoretical Medicine, 129–154 (1999)Google Scholar
  5. Shannon, A.M., Bouchier-Hayes, D.J., Condron, C.M., Toomey, D.: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treatment Reviews 29, 297–307 (2003)CrossRefGoogle Scholar
  6. Siim, B.G., Menke, D.R., Dorie, M.J., Brown, J.M.: Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Research 57, 2922–2928 (1997)Google Scholar
  7. Hanahan, D., Weinberg, R.A.: The hallmarks of cancer, Department of Biochemistry and Biophysics. Cell, 57–70 (2000)Google Scholar
  8. Lartigau, E., Guichard, M.: Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure? International Journal of Radiation Biology 67, 211–216 (1995)CrossRefGoogle Scholar
  9. Kozusko, F., Bajzer, Z.: Combining Gompertzian Growth and Cell Population Dynamics. Mathematical Biosciences 185, 153–167 (2003)MathSciNetzbMATHCrossRefGoogle Scholar
  10. Enderling, H., Chaplain, M.A.J., Anderson, A.R.A., Vaidya, J.S.: A mathematical model of breast cancer development, local treatment and recurrence. Journal of Theoretical Biology 246, 245–259 (2007)MathSciNetCrossRefGoogle Scholar
  11. Byrne, H.M.: Using mathematics to study solid tumour growth. In: The Proceedings of the 9th General Meetings of Euorpean Women in Mathematics, pp. 81–107 (1999)Google Scholar
  12. Byrne, H.M., Chaplain, M.A.J.: Growth of nonnecrotic tumours in the presence and absence of inhibitors. Journal of Mathematical Biosciences 130, 151–181 (1995)zbMATHCrossRefGoogle Scholar
  13. Conde, I.R., Chaplain, M.A.J., Anderson, A.R.A.: Mathematical modeling of cancer cell invasion of tissue. Mathematical and Computer Modelling (2007)Google Scholar
  14. Kim, J.J., Tannock, L.F.: Repopulation of Cancer Cells during Therapy: an Important Cause of Treatment Failure. Nature Cancer Review 5, 516 (2005)CrossRefGoogle Scholar
  15. Brown, J.M.: Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Molecular Medicine Today 6, 157–162 (2000)CrossRefGoogle Scholar
  16. Brown, J.M.: SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer 67, 1163–1170 (1993)CrossRefGoogle Scholar
  17. Folkman, J.: Tumor angiogenesis. Advance Cancer Research 19, 331–358 (1974)CrossRefGoogle Scholar
  18. Vohardsky, J.: Neural model of the Genetic Network. Journal of Biological Chemistry 276, 36168–36173 (2001)CrossRefGoogle Scholar
  19. Patterson, L.H., Mckeown, S.R.: AQ4N: a new approach to hypoxia-activated cancer chemotherapy. British Journal of Cancer 83, 1589–1593 (2000)CrossRefGoogle Scholar
  20. Marcu, L., Olver, I.: Tirapazamine: From Bench to Clinical Trials. Current Clinical Pharmacology 1, 71–79 (2006)CrossRefGoogle Scholar
  21. Preziosi, L., Farina, A.: On decay‘s law for growing porous media. Journal of Non-Linear Mathematic 37, 485–491 (2002)zbMATHGoogle Scholar
  22. Ferrara, N., Kerbel, R.S.: Angiogenesis as a Therapeutic Target. Nature 438, 967–974 (2005)CrossRefGoogle Scholar
  23. Kazmi, N., Hossain, M.A., Phillips, R.M.: Intelligent modeling of benign tumour growth with cell-cell and cell-matrix adhesion. In: 10th IEEE International Conference on Computer and Information Technology (2010)Google Scholar
  24. Gerlee, P., Anderson, A.R.A.: A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. Journal of Theoretical Biology, 705–722 (2007)Google Scholar
  25. Gerlee, P., Anderson, A.R.A.: An evolutionary hybrid cellular automaton model of solid tumour growth. Journal of Theoretical Biology (2007)Google Scholar
  26. Durand, R.E., Olive, P.L.: Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiation Oncology Investigations 5, 213–219 (1997)CrossRefGoogle Scholar
  27. Tse, S.M., Liang, Y., Leung, K.S., Lee, K.H., Mok, T.S.: A mimetic algorithm for multiple-drug cancer chemotherapy schedule optimization. IEEE transaction on systems man, cybernatics 37, 84–91 (2007)CrossRefGoogle Scholar
  28. Algoul, S., Hossain, M.A., Majumderand, M.A.A., Alam, M.S.: Multi-objective optimal chemotherapy model for cancer treatment. Medical Biology Engineering and Computing (2010)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • N. Kazmi
    • 1
  • M. A. Hossain
    • 1
  • R. M. Phillips
    • 2
  1. 1.School of Computing, Engineering and Information SciencesNorthumbria UniversityUK
  2. 2.Institute of Cancer TherapeuticsUniversity of BradfordBradfordUK

Personalised recommendations